HIV-1 superinfection (SI) is the infection of HIV-1 infected individuals by another viral strain. SI has been associated with disease progression, viral recombination and immune escape. Identifying SI remains challenging for various reasons: 1. SI strain may outcompete or be outcompeted by the first strain. 2. SI is difficult to discern from co-infection. 3. SI is difficult to prove within viral subtypes, especially if caused by viruses from similar transmission clusters. 4. Sampling frequencies are too low and systematic screens of large populations to date are missing due to lack of needed longitudinal samples in untreated patients. Here we benefit from historic samples of 2 well characterized longitudinal studies; the Zurich Primary HIV Infection Cohort Study (ZPHI, >360 patients with documented PHI) and the Swiss HIV Cohort Study (SHCS, >19,000 HIV infected individuals).
Sequences of the HIV-1 pol gene from 11,738 patients in the SHCS drug resistance database were used for phylogenetic reconstruction. Then, patients with ≥2 longitudinal sequences were kept. From the distribution of our dataset; 2 criteria were used to select HIV-1 superinfected patients: 1. a phylogenetic cluster diversity of at least 20 patients for each individual patient’s cluster and 2. a genetic distance ≥5% between a patient’s sequences. Finally, to address potential samples mislabelling, patients were categorized on their number of longitudinal sequences and the spatial positioning of these sequences in the phylogeny. Category 1 patients have 2 sequences; categories 2 and 3 patients have >2 sequences and respectively 1 sequence or none spatially away from the others.
Of 4,558 HIV-infected individuals with ≥2 sequences, 330 candidates for HIV-1 superinfection (figure) including 7 enrolled in the ZPHI, were found. 111 patients are men having sex with men, 117 heterosexuals and 90 intravenous drug users. In addition, 123 patients show evidence of ≥ 2 viral subtypes. In category 3, mislabelling can be excluded due to patients’ sequences clustering pattern corresponding to 31 strong candidates for SI. Based on the 25 patients in category 3 and the 1,224 individuals with ≥ 4 longitudinal sequences, we estimated a minimum rate of SI in our cohorts of 2%.
Our molecular epidemiology approach is the largest screen to identify HIV-1 superinfection using longitudinal samples so far. This work sets the basis to validate and characterize HIV-1 SI using next generation sequencing and our cohorts.